The effects of obstructive jaundice on the clinical pharmacodynamics of propofol

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-16008528

Enrollment

Unknown

Registered

2016-05-24

Start date

2016-05-04

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma, Pancreatic cancer

Interventions

Case series:Propofol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing operation with cholangiocarcinoma/pancreatic cancer, aged 35-70 years and weight 45-90 kg.

Exclusion criteria

Exclusion criteria: Patients with known allergy to the study drugs, heart failure (ejection fraction <40%), and/or severe respiratory disease (vital capacity and/or forced expiratory volume <50%) preoperatively were excluded from this study.

Design outcomes

Primary

Measure	Time frame
Requirement of propofol;	—

Countries

China

Contacts

Public ContactJinchao Song

Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

sjch2013@163.com+86 021-81875236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026